Vivos Therapeutics, Inc. (VVOS) got here out with a quarterly lack of $0.28 per share versus the Zacks Consensus Estimate of a lack of $0.43. This compares to lack of $3.05 per share a 12 months in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of 34.88%. 1 / 4 in the past, it was anticipated that this firm would submit a lack of $0.70 per share when it really produced a lack of $0.40, delivering a shock of 42.86%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates two instances.
Vivos Therapeutics
The sustainability of the inventory’s quick value motion based mostly on the recently-released numbers and future earnings expectations will largely rely upon administration’s commentary on the earnings name.
Vivos Therapeutics shares have misplaced about 27.5% for the reason that starting of the 12 months versus the S&P 500’s decline of -5.1%.
What’s Subsequent for Vivos Therapeutics?
Whereas Vivos Therapeutics has underperformed the market to this point this 12 months, the query that involves traders’ minds is: what’s subsequent for the inventory?
There aren’t any simple solutions to this key query, however one dependable measure that may assist traders handle that is the corporate’s earnings outlook. Not solely does this embody present consensus earnings expectations for the approaching quarter(s), but additionally how these expectations have modified these days.
Empirical analysis exhibits a robust correlation between near-term inventory actions and developments in earnings estimate revisions. Buyers can monitor such revisions by themselves or depend on a tried-and-tested score software just like the Zacks Rank, which has a powerful monitor document of harnessing the ability of earnings estimate revisions.
Forward of this earnings release, the estimate revisions pattern for Vivos Therapeutics: combined. Whereas the magnitude and course of estimate revisions may change following the corporate’s just-released earnings report, the present standing interprets right into a Zacks Rank #3 (Maintain) for the inventory. So, the shares are anticipated to carry out according to the market within the close to future. You possibly can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Will probably be attention-grabbing to see how estimates for the approaching quarters and present fiscal 12 months change within the days forward. The present consensus EPS estimate is -$0.41 on $4.1 million in revenues for the approaching quarter and -$1.43 on $18.3 million in revenues for the present fiscal 12 months.
Buyers needs to be aware of the truth that the outlook for the business can have a cloth influence on the efficiency of the inventory as properly. When it comes to the Zacks Trade Rank, Medical – Medicine is at present within the prime 31% of the 250 plus Zacks industries. Our analysis exhibits that the highest 50% of the Zacks-ranked industries outperform the underside 50% by an element of greater than 2 to 1.
One different inventory from the identical business, Lyra Therapeutics, Inc. (LYRA), is but to report outcomes for the quarter ended March 2025.
This firm is predicted to submit quarterly lack of $0.15 per share in its upcoming report, which represents a year-over-year change of +57.1%. The consensus EPS estimate for the quarter has been revised 30.4% decrease during the last 30 days to the present stage.
Lyra Therapeutics, Inc.’s revenues are anticipated to be $0.24 million, down 54.7% from the year-ago quarter.
Ought to You Put money into Vivos Therapeutics, Inc. (VVOS)?
Earlier than you spend money on Vivos Therapeutics, Inc. (VVOS), wish to know the most effective shares to purchase for the following 30 days? Take a look at Zacks Funding Analysis for our free report on the 7 best stocks to purchase.
Zacks Funding Analysis has been dedicated to offering traders with instruments and unbiased analysis since 1978. For greater than 1 / 4 century, the Zacks Rank stock-rating system has greater than doubled the S&P 500 with a median acquire of +24.08% per 12 months. (These returns cowl a interval from January 1, 1988 by Could 6, 2024.)
Vivos Therapeutics, Inc. (VVOS) : Free Stock Analysis Report
Lyra Therapeutics, Inc. (LYRA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
